CAR-T Cell Therapy Market Surges to $ 188.84 billion by 2034 With a CAGR of 36.8% 2025-2034

𝐂𝐀𝐑-𝐓 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐒𝐢𝐳𝐞 𝐑𝐞𝐯𝐞𝐧𝐮𝐞, 𝐎𝐮𝐭𝐥𝐨𝐨𝐤, 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰, 𝐚𝐧𝐝 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬. 𝐓𝐡𝐞 𝐂𝐀𝐑-𝐓 𝐜𝐞𝐥𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 𝐦𝐚𝐫𝐤𝐞𝐭 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 𝐔𝐒𝐃 𝟕.𝟑𝟏 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟒 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐫𝐞𝐝𝐢𝐜𝐭𝐞𝐝 𝐭𝐨 𝐞𝐱𝐩𝐚𝐧𝐝 𝐭𝐨 𝐔𝐒𝐃 𝟏𝟖𝟖.𝟖𝟒 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟒, 𝐰𝐢𝐭𝐡 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟑𝟔.𝟖% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟓 𝐭𝐨 𝟐𝟎𝟑𝟒.

𝐑𝐞𝐩𝐨𝐫𝐭 𝐒𝐜𝐨𝐩𝐞:
This comprehensive study provides an accurate overview of the worldwide CAR-T cell therapy market. Comprehensive analyses of sales volume, price, revenue, market share, and important companies are included. The market is further divided into segments by indication, target antigen, and region in the study, which offers a comprehensive picture of the state of the market.

𝐆𝐞𝐭 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐚𝐠𝐞𝐬 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample

𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐞𝐟𝐢𝐧𝐢𝐭𝐢𝐨𝐧:
CAR-T Cell Therapy (Chimeric Antigen Receptor T-cell Therapy) is an advanced cancer treatment that alters a patient's T-cells to improve their ability to identify and eliminate cancer cells. The procedure entails obtaining T-cells from the patient, altering their genetics to produce a receptor that targets particular cancer antigens, and subsequently reinfusing them back into the patient's body. CAR-T therapy has demonstrated considerable success in treating specific forms of blood cancers, including leukemia and lymphoma.

𝐃𝐫𝐢𝐯𝐞𝐫𝐬 𝐚𝐧𝐝 𝐓𝐫𝐞𝐧𝐝𝐬:
● The therapy's capability to induce lasting remission in certain patients with advanced DLBCL has established it as a groundbreaking treatment. The increasing incidence of DLBCL and heightened understanding of advanced immunotherapies have further amplified the demand for CAR-T therapies.

● Innovations like dual-targeting CARs, armored vehicles, and localized delivery techniques improve the effectiveness and safety profiles of treatments for solid tumors. This expanding body of evidence, along with significant patient demand for innovative treatments, has resulted in heightened investments and research in this field, propelling the advancement of next-generation CAR-T therapies and broadening their use for solid tumors.

𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬:
As the market expands, competition is expected to increase with the involvement of numerous businesses. Here are the top companies in the CAR-T cell therapy market:

• Bluebird Bio
• Celgene Corporation
• Gilead Sciences
• Cellectis
• Servier Laboratories
• Pfizer Inc.
• Merck
• Amgen
• Intellia Therapeutics
• Novartis
• Caribou Biosciences

𝐂𝐀𝐑-𝐓 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

• In terms of indication, the follicular lymphoma (FL) segment is expected to grow at the fastest pace, with a CAGR of 43.2% during the forecast period due to the rising incidence of refractory and high-risk cancer cases.

• Based on target antigen, the CD19/CD22 antigen segment, valued at USD 6,258.5 billion in 2024, held the largest market share owing to its established role in treating B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL).

• In the global market, the North America CAR-T cell therapy market held a 47.16% market share in 2024 due to the presence of advanced healthcare infrastructure, significant research and development investments, and a high prevalence of hematologic malignancies.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐮𝐭𝐥𝐨𝐨𝐤:

By Indication Outlook (Revenue, USD Billion, 2020-2034)
• DLBCL (Diffuse large B-cell lymphoma)
• ALL (Acute Lymphoblastic Leukemia)
• CLL (Chronic Lymphocytic Leukemia)
• MM (Multiple Myeloma)
• FL (Follicular Lymphoma)
• Mastozytosis
• Myeloid Fibrosis
• MLL (Mixed Lineage Leukemia)
• Thymic Cancer
• Glioblastoma
• AML (Acute Myeloid Leukemia)
• Other

By Target Antigen Outlook (Revenue, USD Billion, 2020-2034)
• CD19/CD22
• BCMA (B-Cell Maturation Antigen)
• Others

𝐂𝐨𝐮𝐧𝐭𝐫𝐲-𝐖𝐢𝐬𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬

According to regional analysis, in 2024, North America led the global market, holding about 47% share of the market revenue. The predominance is due to the existence of advanced healthcare facilities, substantial investments in research and development, and a high rate of hematologic cancers.

Also, Europe is anticipated to witness a CAGR of 33.2% during the projection period because of heightened emphasis on broadening access to advanced treatments, along with the growing incidence of relapsed or refractory blood cancers.

• North America (U.S., Canada)
• Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
• Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
• Latin America (Brazil, Mexico, Argentina)
• Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)

𝐌𝐨𝐫𝐞 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐋𝐚𝐭𝐞𝐬𝐭 𝐑𝐞𝐩𝐨𝐫𝐭𝐬 𝐛𝐲 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡:
Artificial Tendons and Ligaments Market
https://www.polarismarketresearch.com/industry-analysis/artificial-tendons-and-ligaments-market

Targeted Protein Degradation Market
https://www.polarismarketresearch.com/industry-analysis/targeted-protein-degradation-market

Hematology Analyzers and Reagents Market
https://www.polarismarketresearch.com/industry-analysis/hematology-analyzers-and-reagents-market

Liposomal Doxorubicin Market
https://www.polarismarketresearch.com/industry-analysis/liposomal-doxorubicin-market

Arthroscopy Market
https://www.polarismarketresearch.com/industry-analysis/arthroscopy-market

𝐂𝐨𝐧𝐭𝐚𝐜𝐭:

Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

𝐀𝐛𝐨𝐮𝐭 𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 & 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠, 𝐈𝐧𝐜:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.